Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Nausea and Vomiting Patients must have signed an IRB-approved informed consent. 2. Patients must be receiving moderately emetogenic chemotherapy for the first time with one of the following neoplasms/regimens Non-small cell lung cancer receiving paclitaxel and carboplatin Breast cancer receiving cyclophosphamide and doxorubicin Colorectal cancer receiving a regimen . 3. Patients must have an ECOG Performance Status of 0 or 1 (see Appendix I). 4. Patients must be >18 years of age. 5. Patients must either be not of child bearing potential or have a negative serum pregnancy test within 7 days prior to registration. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal for at least 12 months. 6. Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for a reasonable time thereafter. 7. Patients must have adequate bone marrow function based on requirements specified in prescribing guidelines for the chemotherapy regimen. 8. Patients must have adequate renal and hepatic function based on requirements specified in prescribing guidelines for the chemotherapy regimen  Patients with pre-existing nausea or vomiting. 2. Patients with other potential causes of nausea or vomiting, including uncontrolled brain metastases, bowel obstruction, or gastrointestinal hemorrhage. 3. Patients with prior adjuvant chemotherapy. 4. Patients receiving concurrent radiotherapy to the brain or upper abdomen. 5. Patients currently taking other antiemetics. 6. Patients who have a history of hypersensitivity to a cannabinoid. 7. Patients with a serious uncontrolled intercurrent medical illness, including serious infection. 8. Patients with a current or previous psychiatric disorder (including manic depressive illness and schizophrenia), as the symptoms of these disease states may be unmasked by the use of cannabinoids. Cesamet should be used with caution in individuals receiving other psychoactive drugs. 9. Patients with hypertension or heart disease, since Cesamet can elevate supine and standing heart rates and cause postural hypotension. 10. Patients with a history of other malignancy within the last 5 years, which could affect the diagnosis or assessment of these study drugs. 11. Any patient who is pregnant or lactating. 12. Any patient who is unable to comply with the requirements of the study